Portal Hypertension Management Market

Market Insights on Portal Hypertension Management covering sales outlook, demand forecast & up-to-date key trend

Portal Hypertension Management Market By Treatment, End Users & Region | Forecast 2023 to 2033

Portal Hypertension Management Market Snapshot (2023 to 2033)

The global portal hypertension management market is expected to reach a valuation of US$ 3.05 billion in 2023, and is projected to exhibit a CAGR of 5% from 2023 to 2033. By the end of the aforementioned forecast period, the market for portal hypertension management is poised to reach US$ 4.97 billion.

Generic drugs presently dominate the market, with the scope of diagnosis including vasopressin and its analogs, beta-blockers, and somatostatin and its analogs. This also shows promising prospects for treatment advancement and research. Moreover, As the most widely used imaging method for identifying portal hypertension, duplex Doppler ultrasonography has witnessed a substantial rise in demand. As a result, this attribute is also expected to spur market growth.

The most frequent cause of portal hypertension is cirrhosis. Cirrhosis is a liver condition that develops when scar tissue substitutes healthy liver cells. As a result, the number of individuals with this condition is expected to fuel market growth. Cirrhosis is more prevalent in men than in women, based on the National Institute of Diabetes and Digestive and Kidney Diseases Trusted Source. As a result, the number of aged inhabitants is anticipated to contribute to a growing market.

Because of high technological advances in health care services and boosting prevalence and occurrence of beta-blocker demand, North America holds the largest market portion. Due to its rising elderly population and elevated prognosis rate, Asia-Pacific has the second-largest market revenue. As a result of consistent increases in the incidence and occurrence of rare diseases, as well as the enhancement of in-patient groups, North America is projected to account for the majority of the market in the years ahead.

The expansion of the liver transplantation segment can be credited to the global rise in demand for transplantable organs. Based on the U.S. Department of Health and Human Services, there were approximately 122,913 diagnoses in the United States hoping for organ transplants in 2019. As a result, sophisticated transplantation items for the intervention of organ damage are in great supply. As a result, the demand for the Liver Transplantation segment is growing. Also, Huge R&D investments, as well as the greater incidence and presence of cardiovascular problems, have expanded the market for beta blocker drugs, which is anticipated to propel this segment's growth during the forecast period. As a result, the Beta Blockers segment is expected to expand significantly.

Constructively approaching reimbursement can have a beneficial impact both during the late phases of the product's creation and long after the product has been launched. Organizations and academics are collaborating to identify obstacles and opportunities that may impact Portal Hypertension R&D. The therapies in development are centered on novel strategies to treat/improve disease symptoms. Companies involved are involved in the development of Portal Hypertension therapies. The introduction of new therapies will have a massive effect on the portal hypertension management market. Considering the aforementioned facts and figures, the market is projected to exhibit a good rate of growth.

Report Attribute	Details
Expected Market Value (2023)	US$ 3.05 Billion
Anticipated Forecast Value (2033)	US$ 4.97 Billion
Projected Growth Rate (2023 to 2033)	5% CAGR

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Portal Hypertension Management Demand Analysis vs. Forecast 2023 to 2033

The pandemic of COVID-19 has had a modest impact on medical systems and the industry. Furthermore, the disease outbreak was disrupting the healthcare supply chain, and several companies relocated to other geographic locations throughout that time to guarantee product availability and safeguard their supply chain. As a result, the market experienced a decline during the historical period.

However, now, that the industries are getting back to their normal functioning, the global demand for Portal Hypertension Management is projected to increase at a CAGR of 5% during the forecast period between 2023 and 2033, reaching a total of US$ 4.97 Billion in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 3%.

Which are Some Prominent Drivers of the Portal Hypertension Management Market?

The increased incidence of portal hypertension in the elderly population is predicted to drive market expansion

Accordance to the American College of Cardiology, amidst getting the highest incidence of hypertension and the elevated risk of CV death and morbidity older adults are usually underdiagnosed for high blood pressure. Based on the National Health and Nutrition Examination Survey (NHANES), hypertension impacts 70% of people over the age of 65 in the United States.

This statistic will keep rising as the population ages. According to a Pew Research Center report, the older population in the United States will thrive to 81 million by 2050, up from 37 million in 2005. Besides this, significant R&D investments, in addition to the increasing proportion and occurrence of cardiovascular problems, have enhanced the demand for portal hypertension drugs.

The increasing incidences of liver cirrhosis propel portal hypertension management market

Based on the National Center for Biotechnology Information (NCBI), liver disease causes nearly 2 million deaths worldwide each year, with 1 million due to cirrhosis comorbidities and 1 million caused by viral hepatitis and hepatocellular carcinoma.

Cirrhosis is presently the 11th major cause of death, and liver cancer is the 16th major cause of death; together, these two diseases account for 3.5% of all global mortality. As a result, the rising prevalence of liver cirrhosis is expected to drive the portal hypertension management market.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

What are the Challenges Projected to be Faced by the Market?

Drugs side effects to Hinder Market Growth

Along with their necessary effects, the drugs may have some unintended consequences. Beta-blockers reduce heart rate. This can result in signs of low blood pressure.

Certain side effects of beta-blockers involve stomach aches, dizziness, diarrhea, or constipation, and also some people experience sexual dysfunction when obtaining them. These are a few of the considerations that the market is likely to face during the projected timeline.

Region-Wise Insights

What Makes North America the Largest Market for Portal Hypertension Management?

Increased prevalence of cardiovascular diseases and liver cirrhosis drive regional market expansion

North America will have the greatest share of the revenue in 2023. The increased incidences of cardiovascular disorders, massive R&D capital, an aging population, well-established infrastructure, and rising demands for beta-blocker drugs are some of the aspects that the market is predicted to benefit from during the forecast timeframe.

Because of the rapid growth of beta blockers in North America, the region is predicted to have the largest market share during the projected period. Furthermore, the pervasiveness of cirrhosis in the United States was estimated to be 0.27% or 633,323 adults. Sixty-nine percent said they were oblivious they had liver disease. As a result, the prevalence of liver cirrhosis in the market is expected to drive market growth.

Why is Asia Pacific Considered a Lucrative Region for the Portal Hypertension Management Market?

Because of the substantial population and expanding number of endoscopy disorder patients in Asia Pacific, the industry for portal hypertension management is anticipated to accelerate at the fastest rate over the projected period.

Furthermore, rising requirements for minimally invasive endoscopic processes and improved healthcare facilities are expected to accelerate the region's market growth. Furthermore, increased federal initiatives to modernize healthcare facilities and the continuous development of a start-up scenery are among the key factors publicizing the region's future growth.

Category-Wise Insights

By End User, which Segment is Projected to Lead the Market?

Hospital Segment is Estimated to Hold the Largest Share

Based on end user, the global Portal Hypertension Management market is segmented into hospital, cardiac center, ambulatory center, and other.

The hospital segment held the largest share of the market in 2022. Moreover, the same segment is expected to register the highest CAGR from 2023 to 2033.

By Treatment, Which Segment is Projected to Lead the Market?

Liver Transplantation Segment is Estimated to Account for the Largest Share

The liver transplantation segment will experience extreme growth in the upcoming years as a consequence of the increasing prevalence of passive lifestyle choices, poor eating habits, alcoholism, and drug addiction, which are among the major aspects cruising the industry's expansion.

The aging population in addition to various charities for liver problems in the world's population, has created a market for liver transplants in different regions. These elements are predicted to propel the liver transplantation market.

Market Competition

Key players in the Portal Hypertension Management market are Ono Pharmaceutical Co., Ltd., Chiasma, Inc., Genextra S.p.a., Gilead Sciences, Inc., Debiovision, Inc., Govind Ballabh Pant Hospital, Dr. Falk Pharma GmbH, Novartis AG, Sun Pharmaceuticals Industries Ltd. Some latest developments by manufacturers are below

ONO obtained approval in Japan for Onoact® for Intravenous Infusion 50mg/150mg ("Onoact"), a short-acting selective 1 blocker, in August 2022.
Gilead Sciences announced in March 2021 that it would expand its collaboration with Novo Nordisk and develop knowledge of the potential for composite strategies in treating individuals with cirrhosis caused by NASH which will further contribute to the portal hypertension management market.

Report Scope

Report Attribute	Details
Market Value in 2023	US$ 3.05 billion
Market Value in 2033	US$ 4.97 billion
Growth Rate	CAGR of 5% from 2023 to 2033
Base Year for Estimation	2022
Historical Data	2018 to 2022
Forecast Period	2023 to 2033
Quantitative Units	Revenue in USD Billion and CAGR from 2023 to 2033
Report Coverage	Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis
Segments Covered	Treatment End User Region
Regions Covered	North America Latin America Europe Asia Pacific Middle East and Africa
Key Countries Profiled	United States Canada Brazil Mexico Germany United Kingdom France Spain Italy India Malaysia Singapore Thailand China Japan South Korea Australia New Zealand GCC Countries South Africa Israel
Key Companies Profiled	Ono Pharmaceutical Co., Ltd. United Therapeutics Corporation Chiasma Inc. Genextra S.p.a. Gilead Sciences Inc. Debiovision, Inc. Govind Ballabh Pant Hospital Dr. Falk Pharma GmbH Novartis AG Sun Pharmaceuticals Industries Ltd.
Customization	Available Upon Request

Key Segments Profiled in the Portal Hypertension Management Industry Survey

By Treatment:

Liver Transplantation
Endoscopic Therapy
- Banding
- Balloon Tamponade
Shunting Procedures
- Nonsurgical Transjugular Intrahepatic Portal Systemic Shunt
- Surgical Shun
Drug Class
- Octapeptides
- Cofactors
- PDE5 Inhibitor
- Beta Blockers

By End Users:

Hospitals
Specialty Clinic
Others

By Region:

North America
Europe
Asia Pacific
Latin America
Middle East and Africa

Frequently Asked Questions

What is the anticipated growth of the Portal Hypertension Management market until 2033?

FMI projects the global Portal Hypertension Management market to expand at a 5% value CAGR by 2033.

What is the estimated market value of the Portal Hypertension Management market expected in 2023?

The global Portal Hypertension Management market is estimated at a market value of US$ 3.05 Billion.

What is the estimated market value of the Portal Hypertension Management market expected in 2033?

The global Portal Hypertension Management market is expected to garner a market value of US$ 4.97 Billion.

Which region is forecast to be the most lucrative for Portal Hypertension Management market growth?

FMI has projected North America to be one of the key regions for the Portal Hypertension Management market.

Which are some prominent Portal Hypertension Management manufacturers?

Ono Pharmaceutical Co., Ltd., Chiasma, Inc., Genextra S.p.a., Gilead Sciences, Inc., Debiovision, Inc., Govind Ballabh Pant Hospital, Dr. Falk Pharma GmbH, Novartis AG, Sun Pharmaceuticals Industries Ltd.

Table of Content

1. Executive Summary | Portal Hypertension Management Market

1.1. Global Market Outlook

1.2. Demand-side Trends

1.3. Supply-side Trends

1.4. Technology Roadmap Analysis

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

3. Market Background

3.1. Market Dynamics

3.1.1. Drivers

3.1.2. Restraints

3.1.3. Opportunity

3.1.4. Trends

3.2. Scenario Forecast

3.2.1. Demand in Optimistic Scenario

3.2.2. Demand in Likely Scenario

3.2.3. Demand in Conservative Scenario

3.3. Opportunity Map Analysis

3.4. Investment Feasibility Matrix

3.5. PESTLE and Porter’s Analysis

3.6. Regulatory Landscape

3.6.1. By Key Regions

3.6.2. By Key Countries

3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

4.2.1. Y-o-Y Growth Trend Analysis

4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment

5.1. Introduction / Key Findings

5.2. Historical Market Size Value (US$ Million) Analysis By Treatment, 2018 to 2022

5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment, 2023 to 2033

5.3.1. Liver Transplantation

5.3.2. Endoscopic Therapy

5.3.2.1. Banding

5.3.2.2. Balloon Tamponade

5.3.3. Shunting Procedures

5.3.3.1. Nonsurgical Transjugular Intrahepatic Portal Systemic Shunt

5.3.3.2. Surgical Shunts

5.3.4. Drug Class

5.3.4.1. Octapeptides

5.3.4.2. Cofactors

5.3.4.3. PDE5 Inhibitors

5.3.4.4. Beta Blockers

5.4. Y-o-Y Growth Trend Analysis By Treatment, 2018 to 2022

5.5. Absolute $ Opportunity Analysis By Treatment, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End Users

6.1. Introduction / Key Findings

6.2. Historical Market Size Value (US$ Million) Analysis By End Users, 2018 to 2022

6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End Users, 2023 to 2033

6.3.1. Hospitals

6.3.2. Specialty Clinics

6.3.3. Others

6.4. Y-o-Y Growth Trend Analysis By End Users, 2018 to 2022

6.5. Absolute $ Opportunity Analysis By End Users, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

7.1. Introduction

7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

7.3.1. North America

7.3.2. Latin America

7.3.3. Europe

7.3.4. Asia Pacific

7.3.5. Middle East and Africa

7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

8.2.1. By Country

8.2.1.1. United States

8.2.1.2. Canada

8.2.2. By Treatment

8.2.3. By End Users

8.3. Market Attractiveness Analysis

8.3.1. By Country

8.3.2. By Treatment

8.3.3. By End Users

8.4. Key Takeaways

9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

9.2.1. By Country

9.2.1.1. Brazil

9.2.1.2. Mexico

9.2.1.3. Rest of Latin America

9.2.2. By Treatment

9.2.3. By End Users

9.3. Market Attractiveness Analysis

9.3.1. By Country

9.3.2. By Treatment

9.3.3. By End Users

9.4. Key Takeaways

10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

10.2.1. By Country

10.2.1.1. Germany

10.2.1.2. United Kingdom

10.2.1.3. France

10.2.1.4. Spain

10.2.1.5. Italy

10.2.1.6. Rest of Europe

10.2.2. By Treatment

10.2.3. By End Users

10.3. Market Attractiveness Analysis

10.3.1. By Country

10.3.2. By Treatment

10.3.3. By End Users

10.4. Key Takeaways

11. Asia Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

11.2.1. By Country

11.2.1.1. China

11.2.1.2. Japan

11.2.1.3. South Korea

11.2.1.4. Singapore

11.2.1.5. Thailand

11.2.1.6. Indonesia

11.2.1.7. Australia

11.2.1.8. New Zealand

11.2.1.9. Rest of Asia Pacific

11.2.2. By Treatment

11.2.3. By End Users

11.3. Market Attractiveness Analysis

11.3.1. By Country

11.3.2. By Treatment

11.3.3. By End Users

11.4. Key Takeaways

12. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By

12.1. Country

12.2. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

12.3. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

12.3.1. By Country

12.3.1.1. GCC Countries

12.3.1.2. South Africa

12.3.1.3. Israel

12.3.1.4. Rest of MEA

12.3.2. By Treatment

12.3.3. By End Users

12.4. Market Attractiveness Analysis

12.4.1. By Country

12.4.2. By Treatment

12.4.3. By End Users

12.5. Key Takeaways

13. Key Countries Market Analysis

13.1. United States

13.1.1. Pricing Analysis

13.1.2. Market Share Analysis, 2022

13.1.2.1. By Treatment

13.1.2.2. By End Users

13.2. Canada

13.2.1. Pricing Analysis

13.2.2. Market Share Analysis, 2022

13.2.2.1. By Treatment

13.2.2.2. By End Users

13.3. Brazil

13.3.1. Pricing Analysis

13.3.2. Market Share Analysis, 2022

13.3.2.1. By Treatment

13.3.2.2. By End Users

13.4. Mexico

13.4.1. Pricing Analysis

13.4.2. Market Share Analysis, 2022

13.4.2.1. By Treatment

13.4.2.2. By End Users

13.5. Germany

13.5.1. Pricing Analysis

13.5.2. Market Share Analysis, 2022

13.5.2.1. By Treatment

13.5.2.2. By End Users

13.6. United Kingdom

13.6.1. Pricing Analysis

13.6.2. Market Share Analysis, 2022

13.6.2.1. By Treatment

13.6.2.2. By End Users

13.7. France

13.7.1. Pricing Analysis

13.7.2. Market Share Analysis, 2022

13.7.2.1. By Treatment

13.7.2.2. By End Users

13.8. Spain

13.8.1. Pricing Analysis

13.8.2. Market Share Analysis, 2022

13.8.2.1. By Treatment

13.8.2.2. By End Users

13.9. Italy

13.9.1. Pricing Analysis

13.9.2. Market Share Analysis, 2022

13.9.2.1. By Treatment

13.9.2.2. By End Users

13.10. China

13.10.1. Pricing Analysis

13.10.2. Market Share Analysis, 2022

13.10.2.1. By Treatment

13.10.2.2. By End Users

13.11. Japan

13.11.1. Pricing Analysis

13.11.2. Market Share Analysis, 2022

13.11.2.1. By Treatment

13.11.2.2. By End Users

13.12. South Korea

13.12.1. Pricing Analysis

13.12.2. Market Share Analysis, 2022

13.12.2.1. By Treatment

13.12.2.2. By End Users

13.13. Singapore

13.13.1. Pricing Analysis

13.13.2. Market Share Analysis, 2022

13.13.2.1. By Treatment

13.13.2.2. By End Users

13.14. Thailand

13.14.1. Pricing Analysis

13.14.2. Market Share Analysis, 2022

13.14.2.1. By Treatment

13.14.2.2. By End Users

13.15. Indonesia

13.15.1. Pricing Analysis

13.15.2. Market Share Analysis, 2022

13.15.2.1. By Treatment

13.15.2.2. By End Users

13.16. Australia

13.16.1. Pricing Analysis

13.16.2. Market Share Analysis, 2022

13.16.2.1. By Treatment

13.16.2.2. By End Users

13.17. New Zealand

13.17.1. Pricing Analysis

13.17.2. Market Share Analysis, 2022

13.17.2.1. By Treatment

13.17.2.2. By End Users

13.18. GCC Countries

13.18.1. Pricing Analysis

13.18.2. Market Share Analysis, 2022

13.18.2.1. By Treatment

13.18.2.2. By End Users

13.19. South Africa

13.19.1. Pricing Analysis

13.19.2. Market Share Analysis, 2022

13.19.2.1. By Treatment

13.19.2.2. By End Users

13.20. Israel

13.20.1. Pricing Analysis

13.20.2. Market Share Analysis, 2022

13.20.2.1. By Treatment

13.20.2.2. By End Users

14. Market Structure Analysis

14.1. Competition Dashboard

14.2. Competition Benchmarking

14.3. Market Share Analysis of Top Players

14.3.1. By Regional

14.3.2. By Treatment

14.3.3. By End Users

15. Competition Analysis

15.1. Competition Deep Dive

15.1.1. Ono Pharmaceutical Co., Ltd.

15.1.1.1. Overview

15.1.1.2. Product Portfolio

15.1.1.3. Profitability by Market Segments

15.1.1.4. Sales Footprint

15.1.1.5. Strategy Overview

15.1.1.5.1. Marketing Strategy

15.1.2. United Therapeutics Corporation

15.1.2.1. Overview

15.1.2.2. Product Portfolio

15.1.2.3. Profitability by Market Segments

15.1.2.4. Sales Footprint

15.1.2.5. Strategy Overview

15.1.2.5.1. Marketing Strategy

15.1.3. Chiasma, Inc.

15.1.3.1. Overview

15.1.3.2. Product Portfolio

15.1.3.3. Profitability by Market Segments

15.1.3.4. Sales Footprint

15.1.3.5. Strategy Overview

15.1.3.5.1. Marketing Strategy

15.1.4. Genextra S.p.a.

15.1.4.1. Overview

15.1.4.2. Product Portfolio

15.1.4.3. Profitability by Market Segments

15.1.4.4. Sales Footprint

15.1.4.5. Strategy Overview

15.1.4.5.1. Marketing Strategy

15.1.5. Gilead Sciences, Inc.

15.1.5.1. Overview

15.1.5.2. Product Portfolio

15.1.5.3. Profitability by Market Segments

15.1.5.4. Sales Footprint

15.1.5.5. Strategy Overview

15.1.5.5.1. Marketing Strategy

15.1.6. Debiovision, Inc.

15.1.6.1. Overview

15.1.6.2. Product Portfolio

15.1.6.3. Profitability by Market Segments

15.1.6.4. Sales Footprint

15.1.6.5. Strategy Overview

15.1.6.5.1. Marketing Strategy

15.1.7. Govind Ballabh Pant Hospital

15.1.7.1. Overview

15.1.7.2. Product Portfolio

15.1.7.3. Profitability by Market Segments

15.1.7.4. Sales Footprint

15.1.7.5. Strategy Overview

15.1.7.5.1. Marketing Strategy

15.1.8. Dr. Falk Pharma GmbH

15.1.8.1. Overview

15.1.8.2. Product Portfolio

15.1.8.3. Profitability by Market Segments

15.1.8.4. Sales Footprint

15.1.8.5. Strategy Overview

15.1.8.5.1. Marketing Strategy

15.1.9. Novartis AG.

15.1.9.1. Overview

15.1.9.2. Product Portfolio

15.1.9.3. Profitability by Market Segments

15.1.9.4. Sales Footprint

15.1.9.5. Strategy Overview

15.1.9.5.1. Marketing Strategy

15.1.10. Sun Pharmaceuticals Industries Ltd.

15.1.10.1. Overview

15.1.10.2. Product Portfolio

15.1.10.3. Profitability by Market Segments

15.1.10.4. Sales Footprint

15.1.10.5. Strategy Overview

15.1.10.5.1. Marketing Strategy

16. Assumptions & Acronyms Used

17. Research Methodology

List of Tables

Table 1: Global Market Value (US$ Million) Forecast by Region, 2023 to 2033

Table 2: Global Market Value (US$ Million) Forecast by Treatment, 2023 to 2033

Table 3: Global Market Value (US$ Million) Forecast by End Users, 2023 to 2033

Table 4: North America Market Value (US$ Million) Forecast by Country, 2023 to 2033

Table 5: North America Market Value (US$ Million) Forecast by Treatment, 2023 to 2033

Table 6: North America Market Value (US$ Million) Forecast by End Users, 2023 to 2033

Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2023 to 2033

Table 8: Latin America Market Value (US$ Million) Forecast by Treatment, 2023 to 2033

Table 9: Latin America Market Value (US$ Million) Forecast by End Users, 2023 to 2033

Table 10: Europe Market Value (US$ Million) Forecast by Country, 2023 to 2033

Table 11: Europe Market Value (US$ Million) Forecast by Treatment, 2023 to 2033

Table 12: Europe Market Value (US$ Million) Forecast by End Users, 2023 to 2033

Table 13: Asia Pacific Market Value (US$ Million) Forecast by Country, 2023 to 2033

Table 14: Asia Pacific Market Value (US$ Million) Forecast by Treatment, 2023 to 2033

Table 15: Asia Pacific Market Value (US$ Million) Forecast by End Users, 2023 to 2033

Table 16: MEA Market Value (US$ Million) Forecast by Country, 2023 to 2033

Table 17: MEA Market Value (US$ Million) Forecast by Treatment, 2023 to 2033

Table 18: MEA Market Value (US$ Million) Forecast by End Users, 2023 to 2033

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 1: Global Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 2: Global Market Value (US$ Million) by End Users, 2023 to 2033

Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033

Figure 4: Global Market Value (US$ Million) Analysis by Region, 2023 to 2033

Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033

Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033

Figure 7: Global Market Value (US$ Million) Analysis by Treatment, 2023 to 2033

Figure 8: Global Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 9: Global Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 10: Global Market Value (US$ Million) Analysis by End Users, 2023 to 2033

Figure 11: Global Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 12: Global Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 13: Global Market Attractiveness by Treatment, 2023 to 2033

Figure 14: Global Market Attractiveness by End Users, 2023 to 2033

Figure 15: Global Market Attractiveness by Region, 2023 to 2033

Figure 16: North America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 17: North America Market Value (US$ Million) by End Users, 2023 to 2033

Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033

Figure 19: North America Market Value (US$ Million) Analysis by Country, 2023 to 2033

Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 22: North America Market Value (US$ Million) Analysis by Treatment, 2023 to 2033

Figure 23: North America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 24: North America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 25: North America Market Value (US$ Million) Analysis by End Users, 2023 to 2033

Figure 26: North America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 27: North America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 28: North America Market Attractiveness by Treatment, 2023 to 2033

Figure 29: North America Market Attractiveness by End Users, 2023 to 2033

Figure 30: North America Market Attractiveness by Country, 2023 to 2033

Figure 31: Latin America Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 32: Latin America Market Value (US$ Million) by End Users, 2023 to 2033

Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033

Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2023 to 2033

Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 37: Latin America Market Value (US$ Million) Analysis by Treatment, 2023 to 2033

Figure 38: Latin America Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 40: Latin America Market Value (US$ Million) Analysis by End Users, 2023 to 2033

Figure 41: Latin America Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 42: Latin America Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 43: Latin America Market Attractiveness by Treatment, 2023 to 2033

Figure 44: Latin America Market Attractiveness by End Users, 2023 to 2033

Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033

Figure 46: Europe Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 47: Europe Market Value (US$ Million) by End Users, 2023 to 2033

Figure 48: Europe Market Value (US$ Million) by Country, 2023 to 2033

Figure 49: Europe Market Value (US$ Million) Analysis by Country, 2023 to 2033

Figure 50: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 51: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 52: Europe Market Value (US$ Million) Analysis by Treatment, 2023 to 2033

Figure 53: Europe Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 54: Europe Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 55: Europe Market Value (US$ Million) Analysis by End Users, 2023 to 2033

Figure 56: Europe Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 57: Europe Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 58: Europe Market Attractiveness by Treatment, 2023 to 2033

Figure 59: Europe Market Attractiveness by End Users, 2023 to 2033

Figure 60: Europe Market Attractiveness by Country, 2023 to 2033

Figure 61: Asia Pacific Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 62: Asia Pacific Market Value (US$ Million) by End Users, 2023 to 2033

Figure 63: Asia Pacific Market Value (US$ Million) by Country, 2023 to 2033

Figure 64: Asia Pacific Market Value (US$ Million) Analysis by Country, 2023 to 2033

Figure 65: Asia Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 66: Asia Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 67: Asia Pacific Market Value (US$ Million) Analysis by Treatment, 2023 to 2033

Figure 68: Asia Pacific Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 69: Asia Pacific Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 70: Asia Pacific Market Value (US$ Million) Analysis by End Users, 2023 to 2033

Figure 71: Asia Pacific Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 72: Asia Pacific Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 73: Asia Pacific Market Attractiveness by Treatment, 2023 to 2033

Figure 74: Asia Pacific Market Attractiveness by End Users, 2023 to 2033

Figure 75: Asia Pacific Market Attractiveness by Country, 2023 to 2033

Figure 76: MEA Market Value (US$ Million) by Treatment, 2023 to 2033

Figure 77: MEA Market Value (US$ Million) by End Users, 2023 to 2033

Figure 78: MEA Market Value (US$ Million) by Country, 2023 to 2033

Figure 79: MEA Market Value (US$ Million) Analysis by Country, 2023 to 2033

Figure 80: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033

Figure 81: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033

Figure 82: MEA Market Value (US$ Million) Analysis by Treatment, 2023 to 2033

Figure 83: MEA Market Value Share (%) and BPS Analysis by Treatment, 2023 to 2033

Figure 84: MEA Market Y-o-Y Growth (%) Projections by Treatment, 2023 to 2033

Figure 85: MEA Market Value (US$ Million) Analysis by End Users, 2023 to 2033

Figure 86: MEA Market Value Share (%) and BPS Analysis by End Users, 2023 to 2033

Figure 87: MEA Market Y-o-Y Growth (%) Projections by End Users, 2023 to 2033

Figure 88: MEA Market Attractiveness by Treatment, 2023 to 2033

Figure 89: MEA Market Attractiveness by End Users, 2023 to 2033

Figure 90: MEA Market Attractiveness by Country, 2023 to 2033